News | March 01, 2024
Briefs: Eugia Pharma Specialities and Eugia SEZ
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Eugia Pharma Specialities restarts production at terminally sterilized product lines
The product is expected to be launched in December 2023
The product is expected to be launched in FY25
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
The product is being launched in August 2023
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
The product is expected to be launched in June 2023
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)